Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates


Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported

Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company
pioneering a new way to treat the underlying cause of severe genetic
diseases by precisely upregulating protein

Stoke Therapeutics Added to NASDAQ Biotechnology Index


Stoke Therapeutics, Inc. (Nasdaq:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update


Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported

Stoke Therapeutics to Present at Upcoming Investor Conferences in November


Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today